Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Journal:
Journal of Clinical Oncology
Published:
DOI:
10.1200/jco-25-00678
Affiliations:
17
Authors:
24
Go to article
Institutions Authors Share
Johnson & Johnson, United States of America (USA)
12.000000
12.000000
 0.50
Institute Gustave-Roussy (IGR), France
2.000000
 0.08
Erasmus MC Cancer Institute, Netherlands
1.000000
 0.04
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)
1.000000
 0.04
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)
1.000000
 0.04
Hospital Universitario Virgen de la Victoria, Spain
1.000000
 0.04
START Madrid-CIOCC, Spain
1.000000
 0.04
Netherlands Cancer Institute (NKI), Netherlands
1.000000
 0.04
Centre Léon Bérard (CLB), France
1.000000
 0.04
Fred Hutchinson Cancer Center, United States of America (USA)
1.000000
 0.04
Hospital Timone, France
1.000000
 0.04
START-Madrid-FJD, Spain
1.000000
 0.04
Interested in Oncology and Carcinogenesis?